Safety of short-term glargine use confirmed

Four separate studies presented today at the American Diabetes Association (ADA) 72nd scientific sessions in Philadelphia suggest the overwhelming balance of evidence puts the drug in the clear.

“We can say that with relatively short term use [glargine] is not associated with cancer but none of us can speak to the longer term use,” US investigator, Dr Laurel Habel (PhD), a research scientist with a special interest in cancer aetiology, told a press briefing on three of the studies. 

Dr Habel, from the Kaiser Permanente Northern California, said her study of 115,000 patients with diabetes on